BridgeBio Pharma, Inc. Common Stock (BBIO) Financials
Key financial figures for BridgeBio Pharma, Inc. Common Stock (Q2 2026).
BridgeBio reported $243.7 million in Q2 2026 total revenue, driven by $222.4 million of U.S. Attruby net product revenue. Total revenue was $243.7 million in Q2 2026, up from $110.6 million in Q2 2025, driven by Attruby (acoramidis) commercial growth. U.S. Attruby net product revenue was $222.4 million, up from $71.5 million a year ago, with growth led by treatment-naive ATTR-CM patients. Royalty revenue was $15.4 million (up from $1.6 million), primarily from BEYONTTRA net product sales in the EU and Japan; license and services revenue was $5.8 million. R&D expense was $149.4 million and SG&A expense was $186.3 million in the quarter. Figures are for Q2 2026, as BridgeBio Pharma, Inc. reported them.
- Revenue
- $244M
- Net Income
- -$156M
- EPS
- $-0.78
- Total Assets
- $1.2B
- Operating Cash Flow
- -$71M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $222M | -$152M | -$0.78 | -48.14% | -$224M |
| Q1 FY2026 | $195M | -$164M | -$0.84 | -54.47% | -$197M |
| Q4 FY2025 | $154M | -$197M | -$1.00 | -120.14% | -$61M |
| Q3 FY2025 | $121M | -$183M | -$0.96 | -120.3% | -$110M |
| Q2 FY2025 | $111M | -$182M | -$0.95 | -121.45% | -$86M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $502M | -$729M | -$3.79 | -113.35% | -$447M |
| FY2024 | $222M | -$536M | -$2.88 | -267.22% | -$522M |
| FY2023 | $9M | -$643M | -$3.95 | -6528.75% | -$529M |
Frequently asked questions
What was BridgeBio Pharma, Inc.'s revenue last quarter?
BridgeBio Pharma, Inc. reported revenue of $222.4 million for Q2 FY2026, up 101.2% from the same period a year earlier.
Is BridgeBio Pharma, Inc. profitable?
Not in its most recent reported period. BridgeBio Pharma, Inc. reported a net loss of $152.2 million for Q2 FY2026, a net margin of -68.43% on revenue.
How has BridgeBio Pharma, Inc.'s margin trended?
Operating margin was -48.14% in Q2 FY2026, compared with -121.45% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did BridgeBio Pharma, Inc. generate?
BridgeBio Pharma, Inc. generated free cash flow of -$223.8 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for BridgeBio Pharma, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.